Organization (Industry)
ReShape Lifesciences (United States)
ClinicalTrials.gov lists ReShape Lifesciences (United States) as lead sponsor of 10 trials.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers ReShape Lifesciences (United States): 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (5)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Obesity | 18 |
| Weight Loss | 5 |
| Obesity, Morbid | 3 |
| Fatty Liver | 1 |
| Non-alcoholic Fatty Liver Disease | 1 |
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2021 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 1 |
| 2015 | 1 |
| 2012 | 2 |
| 2011 | 3 |
| 2010 | 1 |
| 2009 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 1 of 4 hit target (n=4) | not enough data |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| JAMA | 1 |
| Journal of obesity | 1 |
| Obesity surgery | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 51 | 13 | 2025-10-14 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 319,714 | -10,262,007 | 588,258 |
| 2024 | 256,944 | -1,447,461 | 285,391 |
| 2023 | 8,678,000 | -11,387,000 | 2,315,000 |
| 2022 | 11,240,000 | -46,214,000 | 2,537,000 |
| 2021 | 13,600,000 | -63,146,000 | 2,369,000 |
| 2020 | 11,299,000 | -21,630,000 | 3,498,000 |
| 2019 | 3,281,000 | -23,676,000 | 6,893,000 |
| 2018 | 9,101,000 | -37,380,000 | 10,697,000 |
| 2017 | 9,914,000 | -34,765,000 | 10,647,000 |
| 2016 | 3,393,000 | -20,467,000 | 9,872,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (71)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-02-20 | Other financing | not disclosed | Sec extracted |
| 2025-12-17 | Other financing | not disclosed | Sec extracted |
| 2025-11-26 | Other financing | not disclosed | Edgar offerings |
| 2025-08-20 | Other financing | not disclosed | Edgar offerings |
| 2025-08-20 | ATM offering | not disclosed | Sec extracted |
Showing 5 of 71 events.
FDA recalls (1)
| Product | Classification | Initiated |
|---|---|---|
| Obalon Balloon System with Model 4300 Touch Dispenser Touchscreen; Software version 02.00.00.0076 - Product Usage: The System is intended to be used as an adjunct to a moderate intensity diet and behavior modification program. All balloons must be removed 6 months after the first balloon is placed. The Obalon Balloons are administered using the Navigation System. | Class II | 2019-05-23 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| Johns Hopkins University | Co sponsors trial with | 1 |
Latest dated events (141)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-02-20 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-12-17 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-26 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-10-14 | Patent granted | Granted US patents (PatentsView / USPTO) |
| 2025-08-20 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
Showing 5 of 141 events.
Biomarker capability evidence (46)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ATP12A | Trial sponsor | Named in trial inclusion criteria |
| ATP4A | Trial sponsor | Named in trial inclusion criteria |
| CD79B | Trial collaborator | Named in trial inclusion criteria |
| DPP4 | Trial sponsor | Named in trial inclusion criteria |
| GLP1R | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 46 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, approved assets, fda warning letters, fda untitled letters, fda inspection record, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.